Edwards Lifesciences Corporation (NYSE: EW) Stock Competitors & Peer Comparison

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ABT has a market cap of 192.6B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ABT trades at $111.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ABT's P/E ratio is 21.36. In terms of profitability, EW's ROE is +0.10%, compared to ABT's ROE of +0.11%. Regarding short-term risk, EW is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for EW.Check ABT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, EW's ROE is +0.10%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, EW is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for EW.Check BSX-PA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SYK has a market cap of 130.8B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SYK trades at $341.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SYK's P/E ratio is 25.47. In terms of profitability, EW's ROE is +0.10%, compared to SYK's ROE of +0.16%. Regarding short-term risk, EW is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for EW.Check SYK's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, MDT has a market cap of 116B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while MDT trades at $90.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas MDT's P/E ratio is 16.38. In terms of profitability, EW's ROE is +0.10%, compared to MDT's ROE of +0.10%. Regarding short-term risk, EW is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for EW.Check MDT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BSX has a market cap of 76.9B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BSX trades at $51.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BSX's P/E ratio is 16.68. In terms of profitability, EW's ROE is +0.10%, compared to BSX's ROE of +0.15%. Regarding short-term risk, EW is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for EW.Check BSX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, DXCM has a market cap of 34.5B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while DXCM trades at $91.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas DXCM's P/E ratio is 39.26. In terms of profitability, EW's ROE is +0.10%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, EW is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for EW.Check DXCM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, RMD has a market cap of 32.9B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while RMD trades at $226.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas RMD's P/E ratio is 21.06. In terms of profitability, EW's ROE is +0.10%, compared to RMD's ROE of +0.24%. Regarding short-term risk, EW is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for EW.Check RMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, PHG has a market cap of 26.8B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while PHG trades at $27.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas PHG's P/E ratio is 15.64. In terms of profitability, EW's ROE is +0.10%, compared to PHG's ROE of +0.10%. Regarding short-term risk, EW is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for EW.Check PHG's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ZBH has a market cap of 19.3B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ZBH trades at $99.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ZBH's P/E ratio is 11.74. In terms of profitability, EW's ROE is +0.10%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, EW is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for EW.Check ZBH's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ABMD's P/E ratio is 65.36. In terms of profitability, EW's ROE is +0.10%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, EW is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for EW.Check ABMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while PEN trades at $326.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas PEN's P/E ratio is 85.36. In terms of profitability, EW's ROE is +0.10%, compared to PEN's ROE of +0.11%. Regarding short-term risk, EW is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for EW.Check PEN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SNN trades at $30.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SNN's P/E ratio is 14.17. In terms of profitability, EW's ROE is +0.10%, compared to SNN's ROE of +0.12%. Regarding short-term risk, EW is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for EW.Check SNN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ALGN has a market cap of 12.6B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ALGN trades at $176.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ALGN's P/E ratio is 16.06. In terms of profitability, EW's ROE is +0.10%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, EW is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for EW.Check ALGN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SWAV's P/E ratio is 78.76. In terms of profitability, EW's ROE is +0.10%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, EW is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for EW.Check SWAV's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while GMED trades at $85.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas GMED's P/E ratio is 19.36. In terms of profitability, EW's ROE is +0.10%, compared to GMED's ROE of +0.12%. Regarding short-term risk, EW is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for EW.Check GMED's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, GKOS has a market cap of 11.2B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while GKOS trades at $189.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas GKOS's P/E ratio is -220.30. In terms of profitability, EW's ROE is +0.10%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, EW is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for EW.Check GKOS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while PODD trades at $146.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas PODD's P/E ratio is 24.95. In terms of profitability, EW's ROE is +0.10%, compared to PODD's ROE of +0.27%. Regarding short-term risk, EW is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for EW.Check PODD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BIO has a market cap of 9.7B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BIO trades at $361.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BIO's P/E ratio is 38.93. In terms of profitability, EW's ROE is +0.10%, compared to BIO's ROE of +0.03%. Regarding short-term risk, EW is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for EW.Check BIO's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BIO-B trades at $348.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BIO-B's P/E ratio is 103.33. In terms of profitability, EW's ROE is +0.10%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, EW is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for EW.Check BIO-B's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas MASI's P/E ratio is 44.43. In terms of profitability, EW's ROE is +0.10%, compared to MASI's ROE of +0.09%. Regarding short-term risk, EW is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for EW.Check MASI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BRKR has a market cap of 8.8B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BRKR trades at $57.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BRKR's P/E ratio is 29.11. In terms of profitability, EW's ROE is +0.10%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, EW is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for EW.Check BRKR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas NARI's P/E ratio is -59.24. In terms of profitability, EW's ROE is +0.10%, compared to NARI's ROE of -0.00%. Regarding short-term risk, EW is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for EW.Check NARI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while LIVN trades at $82.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas LIVN's P/E ratio is 19.19. In terms of profitability, EW's ROE is +0.10%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, EW is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for EW.Check LIVN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ITGR trades at $125.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ITGR's P/E ratio is 19.69. In terms of profitability, EW's ROE is +0.10%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, EW is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for EW.Check ITGR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, HAE has a market cap of 4.1B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while HAE trades at $90.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas HAE's P/E ratio is 18.06. In terms of profitability, EW's ROE is +0.10%, compared to HAE's ROE of +0.11%. Regarding short-term risk, EW is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for EW.Check HAE's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while IRTC trades at $123.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas IRTC's P/E ratio is -192.44. In terms of profitability, EW's ROE is +0.10%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, EW is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for EW.Check IRTC's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas AXNX's P/E ratio is -709.80. In terms of profitability, EW's ROE is +0.10%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, EW is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for EW.Check AXNX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while TMDX trades at $89.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas TMDX's P/E ratio is 45.50. In terms of profitability, EW's ROE is +0.10%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, EW is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for EW.Check TMDX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while AXGN trades at $48.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas AXGN's P/E ratio is 126.45. In terms of profitability, EW's ROE is +0.10%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, EW is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for EW.Check AXGN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while UFPT trades at $319.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas UFPT's P/E ratio is 32.67. In terms of profitability, EW's ROE is +0.10%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, EW is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for EW.Check UFPT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BFLY trades at $8.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BFLY's P/E ratio is -36.79. In terms of profitability, EW's ROE is +0.10%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, EW is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for EW.Check BFLY's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ESTA trades at $75.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ESTA's P/E ratio is -59.99. In terms of profitability, EW's ROE is +0.10%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, EW is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for EW.Check ESTA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas NUVA's P/E ratio is 75.00. In terms of profitability, EW's ROE is +0.10%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, EW is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for EW.Check NUVA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while NVCR trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas NVCR's P/E ratio is -11.36. In terms of profitability, EW's ROE is +0.10%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, EW is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for EW.Check NVCR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while INSP trades at $58.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas INSP's P/E ratio is 25.62. In terms of profitability, EW's ROE is +0.10%, compared to INSP's ROE of +0.18%. Regarding short-term risk, EW is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for EW.Check INSP's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while TNDM trades at $23.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas TNDM's P/E ratio is -21.03. In terms of profitability, EW's ROE is +0.10%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, EW is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for EW.Check TNDM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ATEC trades at $9.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ATEC's P/E ratio is -162.50. In terms of profitability, EW's ROE is +0.10%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, EW is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for EW.Check ATEC's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while CNMD trades at $49.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas CNMD's P/E ratio is 10.94. In terms of profitability, EW's ROE is +0.10%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, EW is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for EW.Check CNMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ENOV trades at $25.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ENOV's P/E ratio is 7.36. In terms of profitability, EW's ROE is +0.10%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, EW is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for EW.Check ENOV's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while IART trades at $18.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas IART's P/E ratio is 7.73. In terms of profitability, EW's ROE is +0.10%, compared to IART's ROE of -0.01%. Regarding short-term risk, EW is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for EW.Check IART's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while AORT trades at $28.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas AORT's P/E ratio is 47.38. In terms of profitability, EW's ROE is +0.10%, compared to AORT's ROE of -0.01%. Regarding short-term risk, EW is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for EW.Check AORT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas HSKA's P/E ratio is -62.49. In terms of profitability, EW's ROE is +0.10%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, EW is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for EW.Check HSKA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while PRCT trades at $21.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas PRCT's P/E ratio is -11.31. In terms of profitability, EW's ROE is +0.10%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, EW is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for EW.Check PRCT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas AVNS's P/E ratio is 27.77. In terms of profitability, EW's ROE is +0.10%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, EW is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for EW.Check AVNS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while LMRI trades at $12.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas LMRI's P/E ratio is -22.82. In terms of profitability, EW's ROE is +0.10%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, EW is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for EW.Check LMRI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SILK's P/E ratio is -18.96. In terms of profitability, EW's ROE is +0.10%, compared to SILK's ROE of -0.35%. Regarding short-term risk, EW is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for EW.Check SILK's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while IRMD trades at $87.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas IRMD's P/E ratio is 43.80. In terms of profitability, EW's ROE is +0.10%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, EW is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for EW.Check IRMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas FNA's P/E ratio is -19.83. In terms of profitability, EW's ROE is +0.10%, compared to FNA's ROE of -0.35%. Regarding short-term risk, EW is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for EW.Check FNA's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BVS has a market cap of 941M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BVS trades at $13.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BVS's P/E ratio is 18.28. In terms of profitability, EW's ROE is +0.10%, compared to BVS's ROE of +0.28%. Regarding short-term risk, EW is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for EW.Check BVS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, CBLL has a market cap of 882.2M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while CBLL trades at $23.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas CBLL's P/E ratio is -14.26. In terms of profitability, EW's ROE is +0.10%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, EW is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for EW.Check CBLL's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, INMD has a market cap of 873.7M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while INMD trades at $15.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas INMD's P/E ratio is 10.56. In terms of profitability, EW's ROE is +0.10%, compared to INMD's ROE of +0.12%. Regarding short-term risk, EW is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for EW.Check INMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, AVR has a market cap of 868.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while AVR trades at $8.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas AVR's P/E ratio is -4.00. In terms of profitability, EW's ROE is +0.10%, compared to AVR's ROE of -0.78%. Regarding short-term risk, EW is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for EW.Check AVR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas CSII's P/E ratio is -20.83. In terms of profitability, EW's ROE is +0.10%, compared to CSII's ROE of -0.14%. Regarding short-term risk, EW is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for EW.Check CSII's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SIBN has a market cap of 840.4M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SIBN trades at $18.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SIBN's P/E ratio is -55.74. In terms of profitability, EW's ROE is +0.10%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, EW is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for EW.Check SIBN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BBNX has a market cap of 813.4M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BBNX trades at $18.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BBNX's P/E ratio is -11.97. In terms of profitability, EW's ROE is +0.10%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, EW is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for EW.Check BBNX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, VREX has a market cap of 778.9M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while VREX trades at $18.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas VREX's P/E ratio is 19.47. In terms of profitability, EW's ROE is +0.10%, compared to VREX's ROE of +0.05%. Regarding short-term risk, EW is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for EW.Check VREX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, AHCO has a market cap of 775.5M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while AHCO trades at $5.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas AHCO's P/E ratio is 11.63. In terms of profitability, EW's ROE is +0.10%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, EW is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for EW.Check AHCO's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SSII has a market cap of 766.5M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SSII trades at $3.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SSII's P/E ratio is -74.70. In terms of profitability, EW's ROE is +0.10%, compared to SSII's ROE of -0.27%. Regarding short-term risk, EW is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for EW.Check SSII's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BWAY has a market cap of 646M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BWAY trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BWAY's P/E ratio is 41.84. In terms of profitability, EW's ROE is +0.10%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, EW is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for EW.Check BWAY's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, KIDS has a market cap of 642.4M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while KIDS trades at $25.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas KIDS's P/E ratio is -21.19. In terms of profitability, EW's ROE is +0.10%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, EW is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for EW.Check KIDS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, CTKB has a market cap of 631.5M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while CTKB trades at $4.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas CTKB's P/E ratio is -25.91. In terms of profitability, EW's ROE is +0.10%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, EW is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for EW.Check CTKB's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SRDX's P/E ratio is -34.66. In terms of profitability, EW's ROE is +0.10%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, EW is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for EW.Check SRDX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, DCTH has a market cap of 599.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while DCTH trades at $17.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas DCTH's P/E ratio is 1736.00. In terms of profitability, EW's ROE is +0.10%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, EW is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for EW.Check DCTH's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas APEN's P/E ratio is -9.43. In terms of profitability, EW's ROE is +0.10%, compared to APEN's ROE of -0.85%. Regarding short-term risk, EW is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for EW.Check APEN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, CERS has a market cap of 572.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while CERS trades at $2.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas CERS's P/E ratio is -56.69. In terms of profitability, EW's ROE is +0.10%, compared to CERS's ROE of -0.10%. Regarding short-term risk, EW is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for EW.Check CERS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, EW's ROE is +0.10%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, EW is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for EW.Check ZIMV's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, TCMD has a market cap of 534.8M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while TCMD trades at $23.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas TCMD's P/E ratio is 26.94. In terms of profitability, EW's ROE is +0.10%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, EW is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for EW.Check TCMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, NPCE has a market cap of 494.7M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while NPCE trades at $14.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas NPCE's P/E ratio is -22.32. In terms of profitability, EW's ROE is +0.10%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, EW is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for EW.Check NPCE's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, CLPT has a market cap of 462.4M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while CLPT trades at $15.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas CLPT's P/E ratio is -13.07. In terms of profitability, EW's ROE is +0.10%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, EW is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for EW.Check CLPT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SGHT has a market cap of 452.7M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SGHT trades at $8.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SGHT's P/E ratio is -14.86. In terms of profitability, EW's ROE is +0.10%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, EW is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for EW.Check SGHT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, OFIX has a market cap of 411.5M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while OFIX trades at $10.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas OFIX's P/E ratio is -13.30. In terms of profitability, EW's ROE is +0.10%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, EW is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for EW.Check OFIX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, CARL has a market cap of 380.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while CARL trades at $13.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas CARL's P/E ratio is -9.78. In terms of profitability, EW's ROE is +0.10%, compared to CARL's ROE of -0.38%. Regarding short-term risk, EW is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for EW.Check CARL's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while PACB trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas PACB's P/E ratio is -2.80. In terms of profitability, EW's ROE is +0.10%, compared to PACB's ROE of -49.62%. Regarding short-term risk, EW is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for EW.Check PACB's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, PMI has a market cap of 354.8M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while PMI trades at $3.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas PMI's P/E ratio is -2.88. In terms of profitability, EW's ROE is +0.10%, compared to PMI's ROE of +4.99%. Regarding short-term risk, EW is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for EW.Check PMI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, CATX has a market cap of 352.4M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while CATX trades at $3.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas CATX's P/E ratio is -2.19. In terms of profitability, EW's ROE is +0.10%, compared to CATX's ROE of -0.42%. Regarding short-term risk, EW is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for EW.Check CATX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ELMD has a market cap of 351.1M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ELMD trades at $42.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ELMD's P/E ratio is 36.24. In terms of profitability, EW's ROE is +0.10%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, EW is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for EW.Check ELMD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, TLSI has a market cap of 346.7M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while TLSI trades at $5.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas TLSI's P/E ratio is -3.35. In terms of profitability, EW's ROE is +0.10%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, EW is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for EW.Check TLSI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, CV has a market cap of 339.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while CV trades at $6.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas CV's P/E ratio is -2.72. In terms of profitability, EW's ROE is +0.10%, compared to CV's ROE of +1.27%. Regarding short-term risk, EW is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for EW.Check CV's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SENS has a market cap of 323.1M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SENS trades at $7.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SENS's P/E ratio is -3.86. In terms of profitability, EW's ROE is +0.10%, compared to SENS's ROE of -1.66%. Regarding short-term risk, EW is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for EW.Check SENS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas SMLR's P/E ratio is 3.92. In terms of profitability, EW's ROE is +0.10%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, EW is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for EW.Check SMLR's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, TMCI has a market cap of 292.6M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while TMCI trades at $4.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas TMCI's P/E ratio is -4.80. In terms of profitability, EW's ROE is +0.10%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, EW is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for EW.Check TMCI's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, RXST has a market cap of 290.2M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while RXST trades at $7.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas RXST's P/E ratio is -7.54. In terms of profitability, EW's ROE is +0.10%, compared to RXST's ROE of -0.17%. Regarding short-term risk, EW is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for EW.Check RXST's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ANIK has a market cap of 283.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ANIK trades at $21.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ANIK's P/E ratio is 43.20. In terms of profitability, EW's ROE is +0.10%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, EW is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for EW.Check ANIK's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas MGRM's P/E ratio is -12.00. In terms of profitability, EW's ROE is +0.10%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, EW is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for EW.Check MGRM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, PROF has a market cap of 242.4M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while PROF trades at $6.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas PROF's P/E ratio is -5.38. In terms of profitability, EW's ROE is +0.10%, compared to PROF's ROE of -0.56%. Regarding short-term risk, EW is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for EW.Check PROF's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas NVRO's P/E ratio is -1.91. In terms of profitability, EW's ROE is +0.10%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, EW is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for EW.Check NVRO's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, STIM has a market cap of 210.9M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while STIM trades at $3.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas STIM's P/E ratio is -5.61. In terms of profitability, EW's ROE is +0.10%, compared to STIM's ROE of -1.51%. Regarding short-term risk, EW is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for EW.Check STIM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, RCEL has a market cap of 199M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while RCEL trades at $8.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas RCEL's P/E ratio is -5.10. In terms of profitability, EW's ROE is +0.10%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, EW is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for EW.Check RCEL's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas BSGM's P/E ratio is -5.81. In terms of profitability, EW's ROE is +0.10%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, EW is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for EW.Check BSGM's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, LUCD has a market cap of 184.1M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while LUCD trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas LUCD's P/E ratio is -2.61. In terms of profitability, EW's ROE is +0.10%, compared to LUCD's ROE of -0.02%. Regarding short-term risk, EW is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for EW.Check LUCD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas MDGS's P/E ratio is -0.27. In terms of profitability, EW's ROE is +0.10%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, EW is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for EW.Check MDGS's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, FOCL has a market cap of 178M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while FOCL trades at $4.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas FOCL's P/E ratio is -5.80. In terms of profitability, EW's ROE is +0.10%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, EW is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for EW.Check FOCL's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas QIPT's P/E ratio is -15.87. In terms of profitability, EW's ROE is +0.10%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, EW is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for EW.Check QIPT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, INGN has a market cap of 157.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while INGN trades at $5.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas INGN's P/E ratio is -6.38. In terms of profitability, EW's ROE is +0.10%, compared to INGN's ROE of -0.13%. Regarding short-term risk, EW is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for EW.Check INGN's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, QTRX has a market cap of 134.7M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while QTRX trades at $2.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas QTRX's P/E ratio is -1.79. In terms of profitability, EW's ROE is +0.10%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, EW is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for EW.Check QTRX's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, OWLT has a market cap of 114.5M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while OWLT trades at $6.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas OWLT's P/E ratio is -45.21. In terms of profitability, EW's ROE is +0.10%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, EW is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for EW.Check OWLT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas ICAD's P/E ratio is -20.37. In terms of profitability, EW's ROE is +0.10%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, EW is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for EW.Check ICAD's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, HSDT has a market cap of 105.1M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while HSDT trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas HSDT's P/E ratio is -0.02. In terms of profitability, EW's ROE is +0.10%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, EW is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for EW.Check HSDT's competition here

Edwards Lifesciences Corporation (NYSE: EW) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EW stands at 53.3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, EW is priced at $92.56 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EW currently has a P/E ratio of 34.29, whereas HJLI's P/E ratio is N/A. In terms of profitability, EW's ROE is +0.10%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, EW is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for EW.Check HJLI's competition here